The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.

Alexandria Real Estate Equities was among the participants as the drug discovery technology provider closed its series C round.

Each week the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Lyell Immunopharma co-led a series A round for the gene therapy developer, which partially exploits UW research.

The Novo-backed musculoskeletal disease therapy developer's market capitalisation stood at $1.6bn as of close of trading yesterday.

Pfizer Ventures joined existing investors Ipsen and Leaps by Bayer and Pfizer Ventures in a round taking the oncology drug developer's overall funding to $174m.

The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.

The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.

Lyell Immunopharma co-led a series A round for the gene therapy developer, which was spun off by the corporate's co-founders.

The cancer therapy developer, which is commercialising research from University of Texas, has raised series B1 and B2 financing.